Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01006005 |
Recruitment Status
:
Completed
First Posted
: November 2, 2009
Last Update Posted
: November 22, 2012
|
Sponsor:
University of California, San Francisco
Information provided by (Responsible Party):
University of California, San Francisco
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The study is recruiting 50 patients initiating or switching to Atripla and comparing them to 250 individuals previously followed in a prospective study of HIV+ low income individuals recruited from homeless shelters, single room occupancy hotels and free meal food lines as part of the UCSF Reach Study. Adherence will be measured through monthly unannounced pill counts and electronic medication monitors.
Condition or disease |
---|
HIV Infections Adherence |
Study Type : | Observational |
Actual Enrollment : | 51 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens |
Study Start Date : | July 2007 |
Actual Primary Completion Date : | June 2008 |
Actual Study Completion Date : | June 2008 |
Resource links provided by the National Library of Medicine

MedlinePlus related topics:
HIV/AIDS
Drug Information available for:
Atripla
U.S. FDA Resources
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Study Population
HIV infected, marginally housed
Criteria
Inclusion Criteria:
- 18+ years old;
- HIV+;
- Initiating Atripla within 6-months of recruitment;
- Lives in the Tenderloin, South of Market, or Mission District San Francisco;
- Capable of providing informed consent; and
- Willing to complete all study procedures.
Exclusion Criteria:
- Intoxication, cognitive dysfunction or psychosis will preclude potential subjects from informed consent.
No Contacts or Locations Provided
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT01006005 History of Changes |
Other Study ID Numbers: |
IN-US-177-0106 |
First Posted: | November 2, 2009 Key Record Dates |
Last Update Posted: | November 22, 2012 |
Last Verified: | November 2012 |
Keywords provided by University of California, San Francisco:
HIV Treatment experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents |